Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients - Athira Pharma (NASDAQ:ATHA)

Benzinga

Center

High Factuality

Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients - Athira Pharma (NASDAQ:ATHA)

Company to provide overview of Phase 2/3 LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer's disease (AD); LIFT-AD topline data expected in second half of 2024 Two key opinion leaders will discuss ongoing unmet medical need and LIFT-AD's primary endpoint, the Global Statistical Test, designed to measure overall impact on disease Webinar event on Tuesday, June 18th at 11:30 a.m. ET BOTHELL, Wash., June 12, 2024 (GLOBE NEWSWI…